Teva Pharmaceutical Industries Ltd.’s attempts to add a “meaningful” additional market for one of its newer specialty brands, Austedo, have hit the buffers after two late-stage studies failed to show its benefit as a treatment for Tourette’s syndrome.
Teva’s Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials comparing Austedo (deutetrabenazine) tablets with placebo both failed to...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)